WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 526646
Description: VAS3947 is a selective inhibitor of NADPH oxidase activity in low micromolar concentrations, interfering neither with ROS detection nor with XOD or eNOS activities.
MedKoo Cat#: 526646
Chemical Formula: C14H10N6OS
Exact Mass: 310.0637
Molecular Weight: 310.335
Elemental Analysis: C, 54.18; H, 3.25; N, 27.08; O, 5.16; S, 10.33
Synonym: VA-S3947; VA S3947; VAS3947
IUPAC/Chemical Name: 3-Benzyl-7-(2-oxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine
InChi Key: JVZDLDFNSCFLPM-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H10N6OS/c1-2-4-10(5-3-1)8-20-12-11(18-19-20)13(17-9-16-12)22-14-15-6-7-21-14/h1-7,9H,8H2
SMILES Code: C12=NC=NC(SC3=NC=CO3)=C1N=NN2CC4=CC=CC=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 310.335 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Hecht N, Terveer N, Schollmayer C, Holzgrabe U, Meinel L. Opening NADPH oxidase inhibitors for in vivo translation. Eur J Pharm Biopharm. 2017 Jun;115:206-217. doi: 10.1016/j.ejpb.2017.03.001. Epub 2017 Mar 8. PubMed PMID: 28284727.
2: Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol. 2012 May-Jun;56(5-6):216-31. doi: 10.1016/j.vph.2012.02.012. Epub 2012 Mar 3. Review. PubMed PMID: 22405985; PubMed Central PMCID: PMC3378316.
3: Wind S, Beuerlein K, Eucker T, Müller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010 Oct;161(4):885-98. doi: 10.1111/j.1476-5381.2010.00920.x. PubMed PMID: 20860666; PubMed Central PMCID: PMC2970907.